参考文献/References:
[1] Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and
cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian
syndrome[J].Hum Reprod,2001,16(1):36-42.
[2] Petri M, Orbai AM, Alarcón GS,et al. Derivation and validation of the Systemic Lupus
International Collaborating Clinics classification criteria for systemic lupus erythematosus
[J].Arthritis Rheum,2012,64(8):2677-2686. DOI: 10.1002/art.34473.
[3] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on
diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J].Fertil
Steril,2004,81(1):19-25.
[4] Azziz R, Woods KS, Reyna R,et al. The prevalence and features of the polycystic ovary
syndrome in an unselected population[J].J Clin Endocrinol Metab,2004,89(6):2745-2749.
[5] Wild RA, Carmina E, Diamanti-Kandarakis E,et al. Assessment of cardiovascular risk and
prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus
statement by the Androgen Excess and Polycystic Ovary Syndrome(AE-PCOS)Society[J].J Clin
Endocrinol Metab,2010,95(5):2038-2049.DOI: 10.1210/jc.2009-2724.
[6] Fux Otta C, Fiol de Cuneo M, Szafryk de Mereshian P. Polycystic ovary syndrome:
physiopathology review[J].Rev Fac Cien Med Univ Nac Cordoba,2013,70(1):27-30.
[7] Ehrmann DA, Kasza K, Azziz R,et al. Effects of race and family history of type 2 diabetes
on metabolic status of women with polycystic ovary syndrome[J].J Clin Endocrinol Metab,2005,90
(1):66-71.
[8] Moran LJ, Misso ML, Wild RA,et al. Impaired glucose tolerance, type 2 diabetes and
metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis[J].Hum
Reprod Update,2010,16(4):347-363. DOI: 10.1093/humupd/dmq001.
[9] Dunaif A, Wu X, Lee A,et al. Defects in insulin receptor signaling in vivo in the
polycystic ovary syndrome(PCOS)[J].Am J Physiol Endocrinol Metab,2001,281(2):E392-E399.
[10] Corbould A, Zhao H, Mirzoeva S,et al. Enhanced mitogenic signaling in skeletal muscle of
women with polycystic ovary syndrome[J].Diabetes,2006,55(3):751-759.
[11] Hefler-Frischmuth K, Walch K, Huebl W,et al. Serologic markers of autoimmunity in women
with polycystic ovary syndrome[J].Fertil Steril,2010,93(7):2291-2294. DOI:
10.1016/j.fertnstert.2009.01.056.
[12] Du D, Li X. The relationship between thyroiditis and polycystic ovary syndrome: a meta-
analysis[J].Int J Clin Exp Med,2013,6(10):880-889.
[13] Gleicher N, Barad D, Weghofer A. Functional autoantibodies, a new paradigm in autoimmunity
[J]Autoimmun Rev,2007,7(1):42-45.
[14] Petríková J, Lazúrová I, Yehuda S. Polycystic ovary syndrome and autoimmunity
[J].Eur J Intern Med,2010,21(5):369-371. DOI: 10.1016/j.ejim.2010.06.008.
[15] Pasoto SG, Viana VS, Mendonca BB,et al. Anti-corpus luteum antibody: a novel serological
marker for ovarian dysfunction in systemic lupus erythematosus [J]J Rheumatol,1999,26(5):1087-
1093.
[16] Ragab A, Barakat R, Ragheb M,et al. Subfertility treatment in women with systemic lupus
erythematosus[J].J Obstet Gynaecol,2012,32(6):569-571. DOI: 10.3109/01443615.2012.693986.